Daewoong Pharmaceutical Co., Ltd is a middle-of-the-road business: neither the economics nor the price stand out from the peer group. One caution: reported profits have recently run ahead of actual cash, which we track closely.
The price is expensive. You pay 138.7× its owner earnings: the cash an owner could take out each year, which is in the historically expensive zone. At today's price, the market is assuming roughly 33% yearly growth; analysts expect 5%. The market is pricing in far more than analysts expect: heroic expectations.
The trajectory is moderate and the balance sheet is stretched. The company scores 14/20 on our value-creation score: strong value creator.
What to watch: Reported profits have run ahead of actual cash for several periods. As always: this describes the company's numbers; it is not a recommendation.
360° rank · history
1007550250
Jan 20231
58
2023202420252026
All-time high
91
Mar 2026
All-time low
1
Jan 2023
Average rank
41
across all years
Detailed & Historical Ranks
Deep dive into 15 detailed ranks and 3 years of history.
Current202520242023
Price/Sales
59
65
74
52
Price/Earnings
56
44
53
23
Price/Book
48
24
31
24
Dividend Yield
71
27
26
21
Value (overall)
60
34
40
27
Cells are coloured by rank band (red weak → green strong). Sentiment & 360° history begins 2023.